Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director William Aliski sold 6,000 shares of the company’s stock in a transaction dated Friday, December 7th. The shares were sold at an average price of $49.69, for a total value of $298,140.00. Following the completion of the transaction, the director now owns 72,610 shares in the company, valued at approximately $3,607,990.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

William Aliski also recently made the following trade(s):

  • On Thursday, November 8th, William Aliski sold 6,000 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $55.67, for a total value of $334,020.00.
  • On Monday, October 8th, William Aliski sold 19,550 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $72.49, for a total value of $1,417,179.50.

RARE traded down $3.83 on Friday, reaching $46.66. The stock had a trading volume of 604,745 shares, compared to its average volume of 531,054. Ultragenyx Pharmaceutical Inc has a fifty-two week low of $41.67 and a fifty-two week high of $90.98. The stock has a market cap of $2.55 billion, a PE ratio of -6.22 and a beta of 2.36.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, beating the consensus estimate of ($1.94) by $0.20. Ultragenyx Pharmaceutical had a negative return on equity of 40.10% and a negative net margin of 508.70%. The company had revenue of $11.80 million during the quarter, compared to analysts’ expectations of $11.97 million. During the same quarter in the prior year, the firm posted ($1.87) earnings per share. The business’s quarterly revenue was up 5800.0% on a year-over-year basis. As a group, equities analysts forecast that Ultragenyx Pharmaceutical Inc will post -3.99 earnings per share for the current fiscal year.

RARE has been the subject of a number of recent analyst reports. BidaskClub cut Ultragenyx Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 15th. Bank of America increased their price objective on Ultragenyx Pharmaceutical from $72.00 to $94.00 and gave the stock a “buy” rating in a research note on Tuesday, September 11th. SunTrust Banks increased their price objective on Ultragenyx Pharmaceutical to $83.00 and gave the stock a “positive” rating in a research note on Monday, August 20th. Morgan Stanley set a $70.00 target price on Ultragenyx Pharmaceutical and gave the company a “hold” rating in a research note on Monday, October 29th. Finally, Piper Jaffray Companies lowered their price objective on Ultragenyx Pharmaceutical to $70.00 and set an “overweight” rating for the company in a research report on Friday, October 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $76.17.

Hedge funds have recently bought and sold shares of the company. Advisors Asset Management Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $181,000. Pacer Advisors Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at $222,000. Marshall Wace North America L.P. purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at $245,000. Gideon Capital Advisors Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at $303,000. Finally, Janney Montgomery Scott LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at $313,000. Institutional investors own 97.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Ultragenyx Pharmaceutical Inc (RARE) Director William Aliski Sells 6,000 Shares” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/ultragenyx-pharmaceutical-inc-rare-director-william-aliski-sells-6000-shares/2668683.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Read More: Dividend Stocks – Are They Right For You?

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.